Neuronetics Q3 revenue $16.5M (+20% YoY); raises FY2022 guidance to $63-64M

Neuronetics, Inc.

2022-Q3 EPS reported -$1.08 revenue$47,008,000

Q3 revenue $16.5M (+20% YoY); net loss $(7.6)M ($0.28/sh) vs $(8.2)M loss a year ago.
Record US treatment session revenue $11.9M (+16% YoY); NeuroStar system revenue up 51% to $3.9M.
Raised FY2022 revenue guidance to $63-64M from $60-62M; Q4 expected $16-17M.
Received FDA 510(k) clearance for D-Tect MT Accessory; positive TMS coverage policies from CGS and NGS MACs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neuronetics, Inc. reported the three and nine months ended September 30, 2022 results: revenue $16.5 million, net income $(7.6) million, or $(0.28) per share, EPS $(0.28) per share. Guidance raised.

Period: the three and nine months ended September 30, 2022
Revenue: $16.5 million
Net income: $(7.6) million, or $(0.28) per share
EPS: $(0.28) per share
Guidance: raised
Result: reported results

Exact text from the filing

therapies in the world, today announced its financial and operating results for the third quarter of 2022. Third Quarter 2022 Highlights ● Third quarter 2022 revenue of $16.5 million, represents a 20% increase as compared to the third quarter 2021 ● Achieved record quarterly U.S. treatment session revenue of $11.9 million in the third quarter 2022, compared

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.